Summary.-The results are reported of a randomized prospective clinical trial carried out to assess the value of specific active immunotherapy using irradiated autologous tumour cells in patients with glioblastoma multiforme treated by radical surgery and post-operative irradiation. The results in 62 patients show no statistically significant difference in survival between the group receiving adjuvant autologous tumour cells and those treated with surgery and radiotherapy alone. All 27 patients receiving tumour cells were dead at 30 months, whereas 7 of the 35 controls were alive at this time. The results were considered sufficiently discouraging to abandon the trial at this stage on the grounds that there was sufficient evidence in this study that the administration of irradiated autologous cells was of no benefit to patients with high grade astrocytomata.
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THE prognosis for patients with glioblastoma multiforme (Grades III and IV astrocytoma) , which account for 5000 of all glial tumours, is generally regarded as hopeless. The average post-operative survival is approximately 6 months (Craig, Dodge and Svien, 1957; Earle, Rentschler and Snodgrass, 1957) . Freinkel and Gorman (1958) reviewed 219 cases treated by surgery alone of which only 130% were still alive at one year. Although complete excision of a glioblastoma may be accomplished in some cases by hemispherectomy (Matsukado, McCarthy and Kernohan, 1961) , the subsequent mental and neurological deficit is unacceptable.
There is now ample evidence that post-operative radiotherapy in patients with glioblastoma multiforme increases survival, compared with operation alone (Roth and Elvidge, 1960; Taveras, Thompson and Pool, 1962; Hitchcock and Sato, 1964; Jelsma and Bucy, 1969) . Roth and Elvidge (1960) reported a well-17 marked increase in survival with the combined treatment, compared with operation alone, even in cases in which total excision of the tumour appeared to have been accomplished. It seems clear that post-operative irradiation can achieve temporary growth restraint of residual tumour, with resumption of useful life in a proportion of patients for a limited time. Nevertheless, even in the most favourable circumstances, when extensive tumour removal has been accomplished and radical post-operative irradiation given, the 5-year survival rate rarely exceeds 5 0/O.
Methods of improving the effectiveness of irradiation have been sought but no useful advance as yet has been achieved. Heavy particle irradiation (Lawrence, et al., 1962) and also boron capture therapy using slow neutrons (Sweet, Soloway and Brownell, 1961) (Hamilton Fairley, 1969; Currie, 1972) . The present study arose chiefly from the results of an experiment reported by Haddow and Alexander (1964) . These workers found that the injection of irradiated autologous tumour cells in rats bearing a benzpyrene induced fibrosarcoma increased the tumour inhibitory effect of a single large dose of x-rays. This effect may be explained on the grounds of enhanced radiosensitivity of the tumour cells or, alternatively, stimulation of an immunological process which destroyed residual cells following irradiation. The present paper reports the results of a controlled clinical trial designed to see whether the administration of irradiated autologous tumour cells would improve the results of post-operative radiotherapy in high grade astrocytomata of the cerebral hemispheres.
MATERIALS AND METHODS
Criteria for case selection for the trial were: (1) high grade supratentorial astrocytoma, (2) age less than 70 years, (3) suitability for craniotomy. All patients had histologically verified astrocytomata of Grades III or IV malignancy according to the criteria of Kernohan and Sayre (1952 diately from the rest of the tumour material by cutting it into fragments of less than 1 mm diameter with scissors and this was immediately irradiated w%ith a single dose of 15,000 rad (220 kV x-rays, dose rate 800-1000 rad/min) in a flat Petri dish. The aim was to divide the irradiated tumour cell suspension into 3 aliquots of approximately 1 ml of minced tissue, one of which was returned promptly to the neurosurgical unit for immediate injection and the others were stored at -70°C without the addition of a cryopreservative. In many cases, however, there was insufficient non-necrotic material to make up more than one or 2 aliquots for injection.
The tumour material was injected subcutaneously, using a wide bore needle, into the anterior aspect of the left thigh as soon as possible after craniotomy. The remaining 2 aliquots were placed in a 20% solution of dimethyl sulphoxide in culture medium 199, in the proportion of one part cell suspension to 10 parts liquid. The mixture was frozen at 1 'C/min to -50°C and then stored at -196°C. If enough cell suspension wias available, 2 further subcutaneous injections were given during the course of cerebral irradiation, the second into the right thigh when the tumour dose was 1000 rad and the third into the left thigh at 3000 rad. Fig. 2 . According to the tumour site the patient was treated in a prone, supine or lateral head position, whilst wearing a perspex cast to ensure accurate and reproducible daily treatment. The aim was to deliver a maximum tumour dose of 5000 rad in daily fractions (Monday to Friday) over 5 weeks using a 6 million volt linear accelerator. In some cases the treatment time was prolonged because of intercurrent or tumour related problems.
RESULTS
Of a total of 75 patients entered into the trial, 9 died before radiotherapy could be given and 4 were excluded as they were irradiated elsewhere. Postoperative mortality was similar in those who received irradiated tumour cells (4 patients) and those who did not (5 patients). The results of treatment in the remaining group confirm the poor prognosis of patients with glioblastoma multiforme; ( The overall survival according to histological grade (Fig. 4) , soft tissue sarcomata (Morton et al., 1968) , neuroblastoma (Hellstrom et al., 1968) and colonic neoplasms (Gold, 1967 (Hellstrom and Hellstrom, 1970; Currie and Basham, 1972) .
A recent histological study has reported lymphocytic infiltration in 27 of 77 patients (35%) with Grades III or IV astrocytomata (Ridley and Cavanagh, 1971) . This tissue cellular response may represent the morphological features of a host defence mechanism similar to that seen in other human tumours such as breast cancer (Hamlin, 1968; Bloom, Richardson and Field, 1970) , neuroblastoma (Martin and Beckwith, 1968) , seminoma (Dayan, 1966) , and stomach cancer (Black, Opler and Speer, 1956 ). Levy, Mahaley and Day (1972) have reported that patients with glioblastomata and other intracranial neoplasms possessed peripheral blood lymphocytes which were specifically cytotoxic to cultured autologous tumour cells in vitro. They concluded that both anaplastic and welldifferentiated tumours of the central nervous system can induce a tumourspecific, cell-mediated immune response in the host. However, previous attempts by this group to develop tumour specific antisera for treatment of glioblastoma were unsuccessful (Mahaley and Day, 1965; Mahaley, 1968 Mahaley, , 1971 . On the other hand, precipitation between glioblastoma extract and the patient's serum after, but not before, immunization with autologous tumour extract has been reported by Trouillas (1971) . These findings have not been supported by the work of Delpech et al. (1972) who were unable to demonstrate anti-tumour antibody in glioblastoma. In a recent study, Lim and Kluskens (1972) compared antigens from a rat astrocytoma with those from normal rat brain and liver using immunodiffusion and immunoelectrophoresis and reported the presence of antigens that appeared to be specific for the tumour cells. Clearly, further studies are required to establish the presence of tumour associated antigen in human gliomata.
Immunological investigations of malignant gliomata following the administration of irradiated autologous cells must take into consideration the antigenicity of normal brain tissue which may be included in the injected material, as well as the influence which the blood-brain barrier might exert upon cellular and humoral immune mechanisms. In recent years, several normal brain-specific antigens have been identified and partially characterized although their precise role has not been elucidated (Hatcher and MacPherson, 1970) . It is known that under certain conditions animals may react immunologically with their own brain tissue and cause an allergic encephalomyelitis (Paterson, 1966) . Although median survival in our patients was relatively short, there was no evidence for a superimposed acute encephalomyelitis. Under normal conditions proteins cannot cross the bloodbrain barrier but the presence of tumour, a surgical procedure, and perhaps also cerebral irradiation are all situations in which the blood-brain barrier may no longer remain intact and consequently humoral immune mechanisms may be able to operate more readily. On the other hand, if cellular immune mechanisms are implicated chiefly in immunological tumour rejection processes and this seems likely (Alexander and Hamilton Fairley, 1967) , then even an intact blood-brain barrier would not be expected to prevent the passage of sensitized lymphocytes which are known to be capable of migrating through normal vascular endothelium (Gowans, 1959) .
It is possible that immunological mechanisms operate to prevent metastases developing outside the central nervous system. Extra-neurogenic spread from astrocytomata is an exceedingly rare occurrence but it is clear from autografting of viable tumour tissue (Bloom et al., 1960; Grace et al., 1961 ) that typical gliomata can in fact grow at peripheral implantation sites. The occasional occurrence of rapidly growing extracranial deposits in patients with ventriculo-pleural or ventriculo-peritoneal shunts (Wolf, Cowen and Stewart, 1954; Wakamatsu et al., 1971) suggests that the paucity of metastases in glioblastoma is due to mechanical rather than immunological factors.
Bearing in mind the remarkable mobility of the lymphocyte, the mere confinement of cerebral tumours within the central nervous system would not, per se, prevent an immunological reaction from occurring across the blood-brain barrier. Scheinberg and Taylor (1968) have demonstrated that rejection of an intracerebral graft of chemically induced mouse glioblastoma can be achieved by immunizing the animal with tumour cells and Freund's adjuvant. On the other hand, human glioblastomata are usually large and invariably incompletely excised, infiltrating widely and diffusely into brain substance, and it is likely that any immunological reaction, either natural or induced, would be inadequate to control residual tumour growth. Even if specific tumour antigenicity is present, excessive antigen production from a large bulk of tumour might exhaust or paralyse the host's immunological defences (Currie and Basham, 1972 Finally, it is necessary to consider the possible dangers which may be associated with attempts at immunotherapy, such as enhancement of tumour growth which has been encountered in animal experiments (Vaage, 1971; Law et al., 1971) reported after the conclusion of this trial. In most cases in the present study there was good clinical evidence of tumour recurrence and this was proved histologically in 9 of the 10 patients subjected to autopsy. Although the precise cause of death in the remaining patient (E.B., 066110, see above) remains obscure, it should be noted that this patient did not receive autologous tumour cells but was treated with surgery and irradiation alone.
Present methods oftreatment generally fail to achieve more than temporary growth restraint in the great majority of patients with glioblastoma multiforme. Radical surgery and post-operative irradiation are capable of eradicating the tumour in only a very small proportion of patients, but are often valuable in palliation. Against this background of therapeutic failure it is relevant to consider ways in which the management of this tumour can be made more effective.
Extensive necrotic areas in the tumour are frequently present and it is probable that foci of anoxic malignant cells account, at least in part, for the failure of radiotherapy to achieve more than temporary tumour control. Although the clinical history in patients with glioblastoma may be short, tumour growth rate is not necessarily rapid. The tumour mass is often large and relatively small changes in volume within a confined space or involving important cerebral areas are likely to be critical in producing functional disturbance. Johnson et al (1960) (Wilson and Hoshino, 1969) . The use of cytotoxic agents, either before or together with cerebral irradiation, has theoretical advantages which also need to be explored. In a recent randomized trial, however, a combination of irradiation and 5-fluorouracil had no advantage over irradiation alone for patients with glioblastoma (Edland, Javid and Ansfield, 1971 
